Antiretroviral Therapy Perspective

• HIV 2018 Read clinically focused news coverage of key developments from HIV Glasgow 2018.
  Medscape HIV/AIDS, October 2018
• What Doravirine Offers Patients With HIV   Dr Paul Sax describes the trials that led to the approval of doravirine, which might offer some benefits to patients who can't tolerate other NNRTIs.
  Medscape HIV/AIDS, September 2018
• USCA 2018 Read clinically focused news coverage of key developments from UCSA 2018.
  Medscape HIV/AIDS, August 2018
• The New Single-Tablet HIV Drug: How We Might Use It   Dr Paul Sax comments on the place Symtuza™ might occupy in the HIV treatment 'medicine chest.'
  Medscape HIV/AIDS, August 2018
• AIDS 2018 Read clinically focused news coverage of key developments from IAS 2018.
  Medscape HIV/AIDS, June 2018
• Here's What's New in the HIV Treatment Guidelines   Dr Paul Sax reports on a new recommended HIV treatment option and thanks Marty Hirsch for his skillful leadership of the guidelines working group.
  Medscape HIV/AIDS, April 2018
• This Novel, 1-Month Regimen to Prevent TB Is Practice-Changing   Dr Paul Sax reports on an intriguing two-drug regimen that could become the standard of care in preventing TB.
  Medscape HIV/AIDS, March 2018
• The SWORD Study: A New Two-Drug Combo for HIV   Dr Paul Sax highlights the findings of the SWORD study of dolutegravir-rilpivirine and outlines the clinical implications.
  Medscape HIV/AIDS, March 2018
• Get Comfortable With HIV PrEP in Primary Care To prevent HIV from spreading further, primary care clinicians must get comfortable with prescribing and monitoring PrEP.
  Medscape HIV/AIDS, March 2018
• CROI 2018 Read clinically focused news coverage of key developments from CROI 2018.
  Medscape HIV/AIDS, February 2018
• Updated Guideline: Selecting an Initial ART Regimen The New York State Department of Health AIDS Institute provides an outline of current recommendations for preferred and alternative antiretroviral (ART) regimens for adult ART-naive patients.
  Medscape HIV/AIDS, December 2017
• PrEP Safer, More Effective Than Many Physicians Realize PrEP is effective for preventing HIV transmission but underutilized, in part because of misconceptions among physicians.
  Medscape HIV/AIDS, December 2017
• Management of Immune Reconstitution Inflammatory Syndrome The New York State Department of Health AIDS Institute recommends management of IRIS without interruption of ART, except in life-threatening cases.
  Medscape HIV/AIDS, December 2017
• Why Do Women With HIV Have a Higher Heart Attack Risk Than Men? Increased epicardial fat volume is associated with MI in men living with HIV. But does the same hold true for women?
  Medscape HIV/AIDS, August 2017
• Making PrEP Standard of Care Against HIV in the South San Francisco and New York City have made great strides against HIV by putting money into HIV prevention pills. But what about in the South, where the epidemic is most pronounced? Atlanta found a way.
  Medscape HIV/AIDS, August 2017
• Early HIV Therapy and Remission: 'Both Sides of the Coin'   Dr Paul Sax discusses very early antiretroviral therapy in two cases presented at IAS 2017, in which one patient remains in remission and the other does not.
  Medscape HIV/AIDS, August 2017
• Conspiracy Nation: How Unfounded Beliefs Hurt Patients When medical conspiracies go mainstream, the results can be devastating. Can healthcare workers fight back against unscientific ideas?
  Medscape Psychiatry, July 2017
• International AIDS Society (IAS) 2017 Conference Read clinically focused news coverage of key developments from IAS 2017
  Medscape HIV/AIDS, July 2017
• Dilemma: A Competent Patient Who Refuses Recommended Treatment A bioethicist on how to approach patients who refuse life-saving healthcare.
  Medscape Psychiatry, July 2017
• Early Look at Two New Hepatitis C Therapies Dr Nancy Reau shares results on combination treatments expected to be available by late 2017, as well as data on enhanced screening efforts.
  Medscape Gastroenterology, June 2017